TickerFacts.

Autolus Therapeutics plc (AUTL): Total Liabilities

Annual figures by period end, from SEC filings.

$410.94M
As of 2025-12-31
$418.39M
As of 2026-06-30
+29.0%
3-year compound annual growth
+37.3%
5-year compound annual growth
2017-09-30: $6.06M2018-09-30: $17.74M2018-12-31: $21.57M2019-12-31: $48.69M2020-12-31: $84.20M2021-12-31: $92.24M2022-03-31: $92.85M2022-06-30: $99.45M2022-09-30: $102.68M2022-12-31: $191.60M2023-03-31: $193.05M2023-06-30: $221.66M2023-09-30: $225.58M2023-12-31: $263.91M2024-12-31: $355.40M2025-12-31: $410.94M$410.94M
2017-09-30 Total Liabilities (USD) 2025-12-31
Period endedTotal LiabilitiesChange YoYSource filing
2025-12-31$410.94M+15.6%2026-03-27, Balance as of period end
2024-12-31$355.40M+34.7%2026-03-27, Balance as of period end
2023-12-31$263.91Mn/a2025-03-20, Balance as of period end
2023-09-30$225.58Mn/a2024-03-21, Balance as of period end
2023-06-30$221.66Mn/a2024-03-21, Balance as of period end
2023-03-31$193.05Mn/a2024-03-21, Balance as of period end
2022-12-31$191.60Mn/a2024-03-21, Balance as of period end
2022-09-30$102.68Mn/a2024-03-21, Balance as of period end
2022-06-30$99.45Mn/a2024-03-21, Balance as of period end
2022-03-31$92.85Mn/a2024-03-21, Balance as of period end
2021-12-31$92.24M+9.5%2023-03-07, Balance as of period end
2020-12-31$84.20M+72.9%2022-03-10, Balance as of period end
2019-12-31$48.69M+125.8%2021-03-04, Balance as of period end
2018-12-31$21.57Mn/a2020-03-03, Balance as of period end
2018-09-30$17.74M+192.7%2019-02-25, Balance as of period end
2017-09-30$6.06Mn/a2019-02-25, Balance as of period end

Total Liabilities at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedTotal LiabilitiesChange YoY
Autolus Therapeutics plc (AUTL)2025-12-31$410.94M+15.6%
Recursion Pharmaceuticals, Inc. (RXRX)2025-12-31$343.26M-17.0%
Black Diamond Therapeutics, Inc. (BDTX)2025-12-31$30.80M-21.7%
MeiraGTx Holdings plc (MGTX)2025-12-31$250.22M+23.9%
Vir Biotechnology, Inc. (VIR)2025-12-31$237.55M-4.4%
4D Molecular Therapeutics, Inc. (FDMT)2025-12-31$61.05M+22.6%
Champions Oncology, Inc. (CSBR)2026-04-30$22.92M-19.8%
Sutro Biopharma, Inc. (STRO)2025-12-31$306.28M-10.6%
Invivyd, Inc. (IVVD)2025-12-31$35.34M-43.0%

Compare AUTL, RXRX, BDTX, MGTX side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗